Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study

Endothelial progenitor cells (CEPs) and circulating endothelial cells (CECs) are potential biomarkers of response to anti-angiogenic treatment regimens. In the current study, we investigated the effect of docetaxel and sunitinib on CEP/CEC kinetics and clinical response in castration resistant prost...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2014-04, Vol.9 (4), p.e95310-e95310
Main Authors: Fuereder, Thorsten, Wacheck, Volker, Strommer, Sabine, Horak, Peter, Gerschpacher, Marion, Lamm, Wolfgang, Kivaranovic, Danijel, Krainer, Michael
Format: Article
Language:English
Subjects:
Aged
Analysis
Angiogenesis
Biomarkers
Biomarkers, Tumor - metabolism
Bone and Bones - diagnostic imaging
Bone and Bones - drug effects
Bone and Bones - pathology
Bone marrow
Cancer
Cancer cells
Cancer therapies
Castration
Cell Movement - drug effects
Cells (biology)
Chemotherapy
Clinical trials
Disease-Free Survival
Docetaxel
Drug dosages
Endothelial cells
Endothelial Progenitor Cells - drug effects
Endothelial Progenitor Cells - pathology
Endothelium
Humans
Internal medicine
Kinetics
Male
Medicine
Medicine and Health Sciences
Metastasis
Middle Aged
Molecular modelling
Oncology, Experimental
Patients
Pediatrics
Pharmacodynamics
Pharmacology
Prostate cancer
Prostate-Specific Antigen - metabolism
Prostatic Neoplasms, Castration-Resistant - diagnostic imaging
Prostatic Neoplasms, Castration-Resistant - drug therapy
Prostatic Neoplasms, Castration-Resistant - pathology
Radiography
Risk factors
Stem cells
Studies
Taxoids - pharmacology
Taxoids - therapeutic use
Therapy
Toxicity
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Endothelial progenitor cells (CEPs) and circulating endothelial cells (CECs) are potential biomarkers of response to anti-angiogenic treatment regimens. In the current study, we investigated the effect of docetaxel and sunitinib on CEP/CEC kinetics and clinical response in castration resistant prostate cancer (CRPC) patients. Chemonaive patients with CRPC were enrolled in this study to receive either sunitinib (37.5 mg/d), in combination with docetaxel (75 mg/m2) or docetaxel alone. CEP and CEC kinetics were analyzed for every cycle. The primary objective was to compare CEP/CEC pharmacodynamics between both treatment arms. We also investigated if CEC/CEP spikes, induced by MTD docetaxel, are suppressed by sunitinib in patients treated with docetaxel/sunitinib relative to docetaxel monotherapy. A total of 27 patients were enrolled. We observed a significant increase of CEP/CEC (total/viable) counts over time within each cycle (coefficients 0.29233, 0.22092 and 0.26089, respectively; p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0095310